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Fabian first described the use of an intraurethral stent
to relieve infravesical obstruction caused by benign
prostatic hyperplasia [1]. They have also been used
for the management of detrusor sphincter dyssyner-
gia. Urethral stents usually provide initial dramatic
improvements in obstructive voiding symptoms, but
complications are not rare. Stents should be removed
when complications such as recurrent urinary infec-
tions, stent migration, encrustation or recurrent ure-
thral stricture occur.
Hyperbaric oxygen therapy (HBO) aids wound
healing and is thought to support hypoxic tissues until
adequate circulation is reestablished. The beneficial
cellular effects of HBO have been described in several
studies [2]. In urological practice, HBO is mostly used
as an additional modality for the treatment of Fournier
gangrene [3]. Mydlo et al [4] studied a series of 40
penile injuries and suggested that HBO and local
wound care could provide adequate treatment if there
was no progression of gangrene.
Removal of urethral stents can lead to urethral
trauma, urethrorrhagia, and laceration of the external
urethral sphincter. Here we present a case of urethral
stripping caused by endoscopic stent removal, and its
treatment by mechanical replacement of the urethra
and HBO therapy.
CASE PRESENTATION
A 68-year-old man was admitted to our clinic with
acute urinary retention in March 2004. He had a history
of colorectal carcinoma and had undergone a Miles
procedure 2 months earlier. Prostate-specific antigen
concentration and prostate volume were within normal
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Urethral stents usually provide initial, dramatic relief from obstructive voiding symptoms.
However, complications such as recurrent urinary tract infections, stent migration, encrustation
and recurrent urethral strictures are not rare, and stents should be removed when complications
occur. Urethral stent removal is associated with potential risks of urethral injury, bleeding and
external sphincter trauma. Hyperbaric oxygen therapy (HBO) accelerates wound healing by
increasing tissue microcirculation, decreasing capillary pressure and resolving tissue edema.
Although HBO has been used in various urologic applications, there is no report of HBO therapy
being used to treat isolated urethral injuries. Here we present a case of urethral stripping caused
by endoscopic stent removal, and its conservative treatment with HBO therapy.
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ranges. Urinalysis and serum biochemical studies, in-
cluding serum urea and creatinine levels, were normal.
On ultrasonography, both kidneys were normal.
Urethral catheterization was not achieved and a Cys-
tofix was therefore placed. Cystoscopic evaluation
revealed a 3-cm long stricture in the membranous ure-
thra. Internal urethrotomy was performed at the same
session. Despite this procedure, he had lower urinary
tract symptoms including frequency, nocturia and
dysuria. Uroflowmetry revealed peak and average
urinary flow rates of 7 and 4.3mL/second, respectively.
Urethral stent implantation was planned. UroLume
urethral stent implantation was performed in the
membranous urethra in February 2005 (Figure 1).
Stricture and fibrosis of the urethral stent was observed
twice after the procedure, which required visual
internal urethrotomy and transurethral resection of
the obstructive tissue. The patient was hospitalized
twice during this period for complicated urinary tract
infections, and removal of the stent was therefore
planned.
Urethrocystoscopy revealed the stent at the mem-
branous urethra, with edema and erythema of the
surrounding tissue. Uroepithelial tissue covering the
luminal part of the stent was vaporized, and the Uro-
Lume stent was released distally from the urethra.
However, the proximal part of the stent could not 
be released. Removal of the stent using a standard
resection loop and grasping forceps was attempted,
but the proximal part was embedded in the urethra.
Urethral stripping occurred and the urethra and cor-
pus spongiosum were pulled out with the UroLume
stent (Figure 2). The urethra was replaced under the
guidance of an 18-F Foley urethral catheter. The penis
was bandaged with an elastic bandage from the glans
penis to the corpus penis to minimalize the urethral
defect. Immediate empiric adjunctive HBO therapy
was started and administered once a day for 5 days,
at 1,900 mmHg, for 90 minutes per treatment. Broad-
spectrum antibiotics were also administered immedi-
ately after the operation. Recovery was uneventful.
After the removal of the urethral catheter on the 20th
postoperative day, the patient had minor lower urinary
tract symptoms, including dysuria and urgency. Peri-
odic urethral dilatations were being performed every
3 months at the time of writing. No further internal
urethrotomy or resection was required. Blood bio-
chemical parameters, including serum urea and cre-
atinine, remained normal and he had normal urinary
system functions. His peak and average urinary flow
rates were 14 and 8 mL/second, respectively, and he
had minimal lower urinary tract voiding symptoms.
Figure 1. UroLume urethral stent placed in the membranous
urethra.
Figure 2. Urethra and the corpus cavernosum stripping from the
urethral meatus.
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DISCUSSION
Fabian first described the use of an intraurethral stent
to relieve infravesical obstruction caused by benign
prostatic hyperplasia [1], and Milroy et al first used a
urethral stent for the treatment of urethral stricture in
1988 [5]. Since then, several intraurethral stents have
been used, including removable or permanent ones
(which incorporate into the tissue) [5,6] and numer-
ous reports have been published regarding their effi-
cacy. However, the use of metallic and plastic stents
is associated with several potential complications, in-
cluding migration of the stent from its intended posi-
tion, device-related urinary tract infections, intrastent
fibrosis, and the development of encrustations on the
surfaces. These problems can cause significant mor-
bidity and are the major factors limiting the long-
term use of the devices and the major reason for the
removal of the stents [7]. However, urethral stents
have a reported long-term efficacy of 63% in patients
with recurrent urethral strictures. Patients with recur-
rent disease experience intrastent fibrosis and require
either visual internal urethrotomy or transurethral
resection of the obstructive tissue [8].
Removal of the stents may be necessary in the
event of complications, but this can unfortunately
result in urethral trauma, urethrorrhagia, and lacera-
tion of the external urethral sphincter. Few studies
have specifically addressed the problem of urethral
stent removal, and the technical aspects of the proce-
dure and its details have not been thoroughly exp-
lained. In their study, Gajewski et al removed 43 of 44
urethral stents by grasping the prosthesis with uro-
logic straight alligator forceps and pulling it out gently.
Open urethrotomy was required for stent removal in
one patient. Twenty stents were removed intact and
19 were removed wire by wire [9]. Parikh and Milroy
placed the stent completely within a resectoscope
sheath using a guidewire passing through the center
of the stent [10]. Kural et al reported on the successful
use of a holmium—a YAG laser to cut the endopros-
thesis into fragments, allowing the easy and unevent-
ful removal of the stent in one patient [11].
HBO therapy is beneficial for the treatment of prob-
lem wound healing and decompression sickness. It is
thought to support hypoxic tissues until adequate
circulation is reestablished. HBO therapy is usually
administered in a monoplace chamber; the patient is
placed on a movable stretcher, which is rolled inside
on a rail from a matting transport gurney. Several
studies have described the beneficial cellular effects
of HBO [2]. HBO improves tissue oxygenation regu-
lation in diseases caused by tissue hypoxia-ischemia
mechanisms. Studies have demonstrated rapid angio-
genesis and neovascularization in wounds treated with
HBO. Increased oxygen at the site of injury can help to
scavenge oxygen free radicals, which are known to cause
cell damage. Increased levels of molecular oxygen con-
verted by leukocytes to high-energy radicals, such as
superoxide radicals, hydrogen peroxide and hydroxyl
radicals, may perform a bactericidal function.
HBO accelerates wound healing by increasing tis-
sue microcirculation, decreasing capillary pressure and
resolving tissue edema. It is currently used success-
fully in situations of impaired circulation, such as dia-
betic foot. Zamboni et al determined the positive effects
of HBO on the flap life of ischemic flaps [12] and exam-
ined the increase in microcirculation in HBO-exposed
flaps using Doppler ultrasonography. In urological
practice, HBO is mostly used as an additional treat-
ment modality in cases of Fournier gangrene [3]. In a
series of 40 penile injuries, Mydlo et al suggested that
HBO and local wound care could provide adequate
treatment if there was no progression of gangrene [4].
However, despite its widespread use in urological
practice, we were unable to find any report of HBO
used for the treatment of isolated urethral injuries.
In our case, urethral stricture and fibrosis at the site
of the urethral stent was seen twice following ure-
thral stenting, requiring visual internal urethrotomy
and transurethral resection of the obstructive tissue.
Removal of the stent was therefore planned, but the
stent was embedded in the urethra, and urethral strip-
ping occurred. Following the replacement of the ure-
thra, immediate adjunctive HBO therapy was initiated.
No further internal urethrotomy was required during
the postoperative period, but periodic urethral dilata-
tions were performed over a 3-month period.
Urethral stent removal carries a potential risk of
urethral injury, bleeding and external sphincter trauma.
Morcellation of the stent into small pieces and their
extraction through the urethra minimizes these risks.
After the dissection of the distal part of the stent, the
stent can be pushed through the bladder to avoid
broad urethral injuries. If proximal dissection of the
stent is not possible, the complete removal of the stent
through the urethral passage can cause urethral injury
and even urethral stripping, as in our case. In the event
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of urethral injury with stripping, mechanical replace-
ment of the urethra, under the guidance of a Foley
urethral catheter, and subsequent HBO therapy can
provide effective treatment with minimal complica-
tions. To our knowledge, this is the first reported case
of isolated urethral injury treated with HBO and con-
servative therapy.
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